Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial

What Was Tested

The paper reports a study of Exenatide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

Who Took Part

The age groups tagged for this paper are adults.

Adults with CRO (body mass index > 30 kg/m²) without the sign of recurrence of craniopharyngioma in the past year.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Exenatide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

Running at several centres spread the Exenatide study over different clinics and patient groups.

A time span of 26 weeks appears in the methods.

Eleven French University Hospital Centers.

Exenatide or placebo injected subcutaneously twice a day during 26 weeks.

What Was Measured

The subject headings attached to it are Exenatide, Hypoglycemic Agents, Quality of Life, Craniopharyngioma, Obesity, Weight Loss and Feeding Behavior.

Author keywords: glucagon-like peptide-1 analogs, hypothalamic obesity and lifestyle intervention.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide in people with fat loss, obesity & body recomposition over 26 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (European journal of endocrinology), a journal based in England.

More context: the Exenatide compound page, Fat loss, obesity & body recomposition research.